Skip to main content

Table 2 Categorisation 1: non-high FeNO and non-high blood eosinophils vs. high FeNO or high blood eosinophils

From: Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

Characteristics Non-high FeNO and non-high blood eosinophils (n = 200) High FeNO or high blood eosinophils (n = 200) p-value
Sex
 n (% non-missing) 200 (100.0) 200 (100.0) 1.0000
 Male 84 (42.0) 84 (42.0)  
Age
 n (% non-missing) 200 (100.0) 200 (100.0) 0.9223
 Mean (SD) 51.7 (13.1) 51.6 (13.2)  
 Median (IQR) 54.0 (18.5) 53.0 (19.5)  
Age group
 n (% non-missing) 200 (100.0) 200 (100.0) 0.4289
 Under 35 24 (12.0) 25 (12.5)  
 35–65 150 (75.0) 140 (70.0)  
 66–80 26 (13.0) 35 (17.5)  
Smoking status
 n (% non-missing) 200 (100.0) 200 (100.0) 1.0000
 Non-smoker 73 (36.5) 73 (36.5)  
 Ex-smoker 23 (11.5) 23 (11.5)  
 Current smoker 71 (35.5) 71 (35.5)  
BMI
 n (% non-missing) 189 (94.5) 191 (95.5) 0.1025
 Mean (SD) 30.0 (6.9) 29.1 (7.0)  
 Median (IQR) 28.7 (8.1) 27.8 (7.9)  
Active eczema diagnosisa
 n (% non-missing) 200 (100.0) 200 (100.0) 0.3347
 Yes 7 (3.5) 11 (5.5)  
Active rhinitis diagnosisa
 n (% non-missing) 200 (100.0) 200 (100.0) 0.1056
 Yes 55 (27.5) 70 (35.0)  
Eczema diagnosis
 n (% non-missing) 200 (100.0) 200 (100.0) 0.1284
 Yes 54 (27.0) 68 (34.0)  
Rhinitis diagnosis
 n (% non-missing) 200 (100.0) 200 (100.0) 0.0858
 Yes 77 (38.5) 94 (47.0)  
IHD diagnosis
 n (% non-missing) 200 (100.0) 200 (100.0) 1.0000
 Yes 9 (4.5) 9 (4.5)  
Heart failure diagnosis
 n (% non-missing) 200 (100.0) 200 (100.0) 0.3167
 Yes 0 (0.0) 1 (0.5)  
Hypertension diagnosis
 n (% non-missing) 200 (100.0) 200 (100.0) 0.0592
 Yes 55 (27.5) 39 (19.5)  
Diabetes diagnosis
 n (% non-missing) 200 (100.0) 200 (100.0) 0.8630
 Yes 19 (9.5) 18 (9.0)  
GERD active diagnosis
 n (% non-missing) 200 (100.0) 200 (100.0) 0.0630
 Yes 35 (17.5) 22 (11.0)  
Predicted peak flow
 n (% non-missing) 105 (52.5) 110 (55.0) 0.7422
 Mean (SD) 516.0 (73.2) 519.4 (75.8)  
 Median (IQR) 485.8 (134.7) 487.6 (137.8)  
ICS/LABA prescriptions per patient
 n (% non-missing) 200 (100.0) 200 (100.0) 0.4736
 Mean (SD) 4.1 (4.0) 4.1 (3.7)  
 Median (IQR) 3.0 (5.0) 3.5 (5.0)  
Mono ICS prescriptions per patient
 n (% non-missing) 200 (100.0) 200 (100.0) 0.0112
 Mean (SD) 1.4 (2.7) 0.6 (1.6)  
 Median (IQR) 0.0 (1.0) 0.0 (0.0)  
Mean daily SABA dosage (µg)
 n (% non-missing) 200 (100.0) 200 (100.0) 0.2808
 < 100 67 (33.5) 83 (41.5)  
 100–200 58 (29.0) 47 (23.5)  
 201–400 45 (22.5) 47 (23.5)  
 > 400 30 (15.0) 23 (11.5)  
ICS adherenceb
 n (% non-missing) 200 (100.0) 200 (100.0) 0.1931
 Mean (SD) 72.2 (72.7) 63.3 (53.3)  
 Median (IQR) 61.7 (64.4) 52.0 (61.7)  
  1. All values in table are n (%) unless otherwise specified. High FeNO defined as ≥ 50 ppb; non-high FeNO < 25 ppb; high blood eosinophil count defined as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
  2. ATS American Thoracic Society, BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
  3. aActive denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
  4. bMedication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period for all patients was 365 days in the study year